The Hindu Business Line
Emcure rolls out generic version of Eisai’s breast cancer drug
At a time when cancer drugs are on the government’s price radar, Pune-based drugmaker Emcure Pharmaceuticals said it was launching its version of breast cancer drug Eribulin, at 40 per cent less than the original drug.
Emcure’s “Eribilin” is touted to be the first generically similar version of the innovator drug Halaven (Eribulin), sold by Japanese drugmaker Eisai Pharmaceuticals to treat metastatic breast cancer.
Sainath Iyer, Emcure’s President (emerging and super speciality business), said that Eribulin was on the list of 42 cancer drugs whose trade margins Emcure’s Eribilin is priced at ₹19,500 per vial, compared to Eisai’s about ₹31,000
The total treatment cost for four cycles (involving four vials per cycle) worked out to over ₹3 lakh for the patient
were capped by the government recently at 30 per cent.
Emcure’s Eribilin is priced at ₹19,500 per vial, compared to Eisai’s about ₹31,000. The total treatment cost for four cycles (involving four vials per cycle) worked out to over ₹3 lakh for the patient. The drug’s production is presently outsourced, but as volumes increase, the price could see a revision downwards, Iyer indicated.
Eribulin is used in the second line of treatment of triple-negative breast cancers, or when the cancer has become resistant to the first line of chemotherapy. And generic Eribulin is a research landmark, said Mukund Gurjar, Emcure’s Chief Scientific Officer, in terms of producing both the active pharmaceutical ingredient and the formulation.
For the ₹4,500-crore Emcure, the oncology division clocks about ₹150 crore, said Iyer.
The company is looking to build its pipeline of products, including biosimilar products, and the first one is about a year away, he said.